Navigation Links
Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
Date:8/10/2011

iscovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031 and LX1033, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX1031 and LX1033. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
2. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
3. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
4. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
5. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
6. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
7. Lexicon to Provide First Quarter 2011 Financial Results
8. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
9. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
11. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... YORK , May 20, 2013  Echo Pharma ... 2.5 of the Irish Takeover Rules (the "Announcement"), a ... plc (NYSE: ELN ) to $12.50 per ... cash confirmed and not conditional on due diligence.  The ... Royalty Pharma has reserved the right to waive down ...
(Date:5/20/2013)... , May 20, 2013  Atlantic Pharmaceuticals, Inc., ... is commercializing a unique technology to deter prescription ... President, Anthony Soscia , has ... Atlanta Business Chronicle ,s Health-Care Heroes Awards. The ... Business Chronicle to honor individuals and organizations demonstrating ...
(Date:5/20/2013)... May 20, 2013  Rhythm announced today the presentation ... higher prevalence of gastroparesis symptoms among diabetic patients in ... is high among patients with both type 1 and ... among those with the more common type 2 disease. ... MD, PhD, Associate Professor of Medicine at Harvard Medical ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
(Date:5/20/2013)... NL, 20 May 2013 While Huntington,s disease ... anticipates that new disease-modifying therapies in development may ... of HD research depends upon the identification of ... evaluate therapies, and these biomarkers may eventually be ... could be especially helpful to monitor changes during ...
(Date:5/20/2013)... Horizon NJ Health, New Jersey’s largest ... it has earned a Commendable Accreditation status from ... Health is a wholly owned subsidiary of Horizon Blue ... Health Plan Accreditation is a nationally recognized program that ... plans provide to their members. Health Plan Accreditation performance ...
(Date:5/20/2013)... May 20, 2013 The American Society ... for Bright Pink®, the organization that empowers young women to ... end of 2012. Thanks to its members, ASCP raised more ... is involved in Relay for Life at the local level. ... he decided to donate. “I was made aware of the ...
(Date:5/20/2013)... The nationwide law firm of Bernstein Liebhard LLP ... imaging (MRI) can be used to predict metal-on-metal hip ... experiencing symptoms. According to an article published on May ... MRI detected synovitis (tissue damage) in 68% of asymptomatic patients ... causes, the detection rate was 75%, while MRIs were able ...
(Date:5/20/2013)... MONDAY, May 20 (HealthDay News) -- Boys who are ... likely to become obese adults as those who didn,t ... 30-year study shows. Researchers found that men with ... (BMI) and obesity, even if they no longer had ... well-off or poor, they tended toward obesity. "The ...
Breaking Medicine News(10 mins):Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 2Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 2Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 4Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3
... Researchers may have found a more potent risk factor for melanoma ... disease. In a new study, scientists at NYU Langone Medical Center ... of melanoma in women under the age of 50. The ... Clinical Cancer Research and will be published in the ...
... N.C. Numerous studies have shown a relationship between ... with breast cancer. In a study published today in ... , an investigation of coping strategies and quality of ... QOL determines the use of coping strategies. , "It ...
... March 24 The American Cancer Society Cancer Action ... and the Campaign for Tobacco-Free Kids applaud Senator Frank ... Drug Administration to exert its authority and immediately remove ... quoted numerous times in many publications during the past ...
... emphasizes values-based curriculum PHOENIX, March 24 In answer ... the need for more values-driven leaders, Grand Canyon ... it rewards to high academic achievers as well as ... is our own higher education stimulus package," said GCU ...
... educate Americans about their risk of type 2 diabetesPORT ST. ... Day. The American Diabetes Association urges all Americans to ... it. To help educate the public, the American Diabetes ... Supply, Inc., have teamed up to provide an online video ...
... behavioral traits, susceptibility to certain diseases , , TUESDAY, ... 1,362 copy number variations (CNVs) in the human genome ... -- differences in gene copy numbers caused by deletions, ... a large amount of human diversity and can also ...
Cached Medicine News:Health News:NYU study finds new risk factor for melanoma in younger women 2Health News:NYU study finds new risk factor for melanoma in younger women 3Health News:Quality of life may impact coping strategies of young women with breast cancer 2Health News:Quality of life may impact coping strategies of young women with breast cancer 3Health News:Statement of the American Cancer Society Cancer Action Network, American Heart Association, American Lung Association and the Campaign for Tobacco-Free Kids 2Health News:Grand Canyon University Increases Academic Scholarships 2Health News:Grand Canyon University Increases Academic Scholarships 3Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 2Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 3Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 4Health News:Study IDs Variations in Black, White Genomes 2
Reciprocating shaker specifically for platelet bags....
... by the adrenal cortex, the corpus luteum, ... other steroids, progesterone is synthesized from cholesterol ... Progesterone produced by the adrenal cortex and ... steroidogenic pathways, with only a small amount ...
No cross-reaction with human pro-insulin and C-peptide....
ELISA for the detection of Insulin....
Medicine Products: